Ngole P M
Drug Intell Clin Pharm. 1987 Jun;21(6):512-4. doi: 10.1177/106002808702100606.
A case of intravenous labetalol in the treatment of a resistant hypertensive emergency is reported. Although there have been several reports of the use of oral labetalol in resistant hypertension, no intravenous administration in hypertensive emergency resistant to other drugs has been reported to date. A 36-year-old black female with BP of 270/160 mm Hg with complaints greater than one month's duration of dizziness, severe headaches, blurred vision, shortness of breath, vomiting, palpitations, flushing, agitation, diarrhea, weakness, and weight loss, was treated successfully with intravenous labetalol after she failed to respond to other established parenteral antihypertensive drugs. The patient received labetalol 20 mg iv bolus, and then 20 mg every ten minutes until a cumulative dose of 200 mg was attained. Labetalol produced a prompt but smooth reduction in BP without any reflex tachycardia or other adverse effects. Intravenous labetalol may be safe and effective for the management of rapid BP control in hypertensive emergencies resistant to other parenteral antihypertensive agents.
报告了一例静脉注射拉贝洛尔治疗顽固性高血压急症的病例。尽管已有多篇关于口服拉贝洛尔用于顽固性高血压的报道，但迄今为止，尚无关于在对其他药物耐药的高血压急症中静脉给药的报道。一名36岁黑人女性，血压为270/160 mmHg，有持续一个多月的头晕、严重头痛、视力模糊、呼吸急促、呕吐、心悸、潮红、烦躁、腹泻、虚弱和体重减轻等症状，在对其他已确立的胃肠外抗高血压药物无反应后，静脉注射拉贝洛尔治疗成功。患者静脉推注拉贝洛尔20 mg，然后每十分钟注射20 mg，直至累积剂量达到200 mg。拉贝洛尔使血压迅速但平稳下降，无任何反射性心动过速或其他不良反应。静脉注射拉贝洛尔对于治疗对其他胃肠外抗高血压药物耐药的高血压急症中的快速血压控制可能是安全有效的。
